Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy

Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy

Abstract We aim to determine the feasibility of a novel radiomic biomarker that can integrate with other established clinical prognostic factors to predict progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) undergoing first-line immunotherapy. Our study includes 107...

Full description

Bibliographic Details
Main Authors: Apurva Singh, Hannah Horng, Leonid Roshkovan, Joanna K. Weeks, Michelle Hershman, Peter Noël, José Marcio Luna, Eric A. Cohen, Lauren Pantalone, Russell T. Shinohara, Joshua M. Bauml, Jeffrey C. Thompson, Charu Aggarwal, Erica L. Carpenter, Sharyn I. Katz, Despina Kontos
Format: Article
Language:English
Published: Nature Portfolio 2022-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-14160-7

Internet

https://doi.org/10.1038/s41598-022-14160-7

Similar Items